These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 22768010

  • 1. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations.
    Prescott WA.
    J Pediatr Pharmacol Ther; 2011 Oct; 16(4):262-9. PubMed ID: 22768010
    [Abstract] [Full Text] [Related]

  • 2. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA.
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [Abstract] [Full Text] [Related]

  • 3. Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.
    Zobell JT, Epps K, Kittell F, Sema C, McDade EJ, Peters SJ, Duval MA, Pettit RS.
    J Pediatr Pharmacol Ther; 2016 Sep; 21(3):239-46. PubMed ID: 27453702
    [Abstract] [Full Text] [Related]

  • 4. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
    Ochs MA, Dillman NO, Caverly LJ, Chaffee VD.
    Pediatr Pulmonol; 2021 Dec; 56(12):3634-3643. PubMed ID: 33983680
    [Abstract] [Full Text] [Related]

  • 5. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA, Nagel JL.
    Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
    [Abstract] [Full Text] [Related]

  • 6. Vancomycin Dosing and Monitoring in the Treatment of Cystic Fibrosis: Results of a National Practice Survey.
    Pettit RS, Peters SJ, McDade EJ, Kreilein K, Patel R, Epps K, Kittell F, Duval MA, Zobell JT.
    J Pediatr Pharmacol Ther; 2017 Jan; 22(6):406-411. PubMed ID: 29290740
    [Abstract] [Full Text] [Related]

  • 7. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP.
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [Abstract] [Full Text] [Related]

  • 8. Exploring the Relationship between FEV1 Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies.
    Hoff BM, Scheetz MH, Jain M, Cullina JF, Rhodes NJ.
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [Abstract] [Full Text] [Related]

  • 9. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD002009. PubMed ID: 22336782
    [Abstract] [Full Text] [Related]

  • 10. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2010 Jan 20; (1):CD002009. PubMed ID: 20091528
    [Abstract] [Full Text] [Related]

  • 11. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2014 Feb 04; (2):CD002009. PubMed ID: 24497229
    [Abstract] [Full Text] [Related]

  • 12. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
    Phillips JA, Bell SC.
    Intern Med J; 2001 Feb 04; 31(1):23-6. PubMed ID: 11478352
    [Abstract] [Full Text] [Related]

  • 13. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
    Albright JC, Houck AP, Pettit RS.
    Pediatr Pulmonol; 2020 Oct 04; 55(10):2662-2666. PubMed ID: 32568427
    [Abstract] [Full Text] [Related]

  • 14. High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital Pharmacists.
    Roy C, Gray C, Ruda L, Bell A, Bolt J.
    Can J Hosp Pharm; 2016 Oct 04; 69(5):367-375. PubMed ID: 27826154
    [Abstract] [Full Text] [Related]

  • 15. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Tan KH.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD002009. PubMed ID: 16855982
    [Abstract] [Full Text] [Related]

  • 16. Once daily dosing of aminoglycosides in pediatric cystic fibrosis patients: a review of the literature.
    Wassil SK, Fox KM, White JW.
    J Pediatr Pharmacol Ther; 2008 Apr 19; 13(2):68-75. PubMed ID: 23055867
    [Abstract] [Full Text] [Related]

  • 17. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
    Soulsby N, Bell S, Greville H, Doecke C.
    Intern Med J; 2009 Aug 19; 39(8):527-31. PubMed ID: 19220547
    [Abstract] [Full Text] [Related]

  • 18. Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis.
    Deschamp AR, Pettit RS, Donaldson JA, Slaven JE, Davis SD.
    SAGE Open Med; 2017 Aug 19; 5():2050312117736694. PubMed ID: 29085640
    [Abstract] [Full Text] [Related]

  • 19. Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.
    Cogen JD, Oron AP, Gibson RL, Hoffman LR, Kronman MP, Ong T, Rosenfeld M.
    Pediatrics; 2017 Feb 19; 139(2):. PubMed ID: 28126911
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
    Staubes BA, Metzger NL, Walker SD, Peasah SK.
    Pharmacotherapy; 2016 Jun 19; 36(6):623-30. PubMed ID: 27138730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.